China coronary secondary prevention study (CCSPS): outcomes from analysis of coronary heart disease patients with diabetes.
- Author:
Zong-liang LU
1
;
Bao-min DU
;
Zuo CHEN
;
Yang-feng WU
;
Xue-hai YU
;
Yu-chen ZHAO
;
null
Author Information
- Publication Type:Journal Article
- MeSH: Aged; China; Coronary Disease; complications; drug therapy; prevention & control; Diabetes Mellitus; Double-Blind Method; Drugs, Chinese Herbal; therapeutic use; Female; Follow-Up Studies; Humans; Hypolipidemic Agents; therapeutic use; Male; Middle Aged; Secondary Prevention
- From: Chinese Journal of Cardiology 2005;33(12):1067-1070
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo elucidate whether lipid-lowering therapy with Xuezhikang can induce a decrease of cardiac events and an attenuation of total mortality in coronary heart disease (CHD) patients with diabetes.
METHODSWe designed a random, double-blinded, placebo controlled clinical trial in selected 591 patients. All patients were administrated with capsule Xuezhikang (0.6 g, Bid) or placebo in addition to conventional therapy. The mean follow-up period was four years. The primary end-points were nonfatal myocardial infarction and death from CHD.
RESULTS(1) The incidence of CHD events and that of death from CHD were reduced by 50.8% (P = 0.0008) and by 44.1% (P = 0.0246) in treatment group, respectively; Also, the incidence of nonfatal myocardial infarction was reduced by 63.8% (P = 0.0151). (2) The incidence of stroke, tumor, and PCI/CABG were decreased by 20.2%. (3) The total mortality were lowered by 44.1% in treatment group (P = 0.0097).
CONCLUSIONXuezhikang can effectively reduce the incidence of cardiac events and total mortality in CHD patients with diabetes.
